Damora Therapeutics
NASDAQ: DMRACopenhagen, US · 3 known investors
Advancing potentially best-in-class therapeutics for myeloproliferative neoplasms.
Founders & leadership
Board
CC
Christopher CainBoard director
CG
Carl GoldfischerBoard director
PH
Peter HarwinBoard director
AM
Amit MunshiBoard director
JD
Jayson DallasBoard director
JB
Julianne BrunoBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$428.3M disclosed across 3 rounds · 2019–2025
▶$285MraisedNov 2025 · 48 investors · BiotechnologyRule 506(b)
▶$285MraisedNov 2025 · 48 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher CainDirector
- Garrett WinslowExecutive Officer
- Carl GoldfischerDirector
- Lori FirmaniExecutive Officer
- Peter HarwinDirector
- Amit MunshiDirector
- Hans T. SchambyeExecutive Officer, Director
- Jayson DallasDirector
- Julianne BrunoDirector
- Offering amount
- $285M
- Amount sold
- $285M
- Finders' fees
- $17.1M
- Placement agents
- UBS Securities LLC, Leerink Partners LLC, LifeSci Capital, LLC, Jefferies LLC
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$64.2MraisedNov 2020 · 42 investors · PharmaceuticalsRule 506(b)
▶$64.2MraisedNov 2020 · 42 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jon FreveExecutive Officer
- Karen WagnerDirector
- Chandra LeoDirector
- Soren MollerDirector
- Soren LemoniusDirector
- Stephan ChristgauDirector
- David ShapiroDirector
- Chao Q. KhuongDirector
- Carl GoldfischerDirector
- Amit MunshiDirector
- Hans SchambyeExecutive Officer, Director
- Erez ChimovitsDirector
- Offering amount
- $64.2M
- Amount sold
- $64.2M
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$79.1MraisedJan 2020 · 35 investors · PharmaceuticalsRule 506(b)
▶$79.1MraisedJan 2020 · 35 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jakob Dynnes HansenExecutive Officer
- Hans SchambyeExecutive Officer
- Offering amount
- $123.7M
- Amount sold
- $79.1M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Damora Therapeutics do?
- Advancing potentially best-in-class therapeutics for myeloproliferative neoplasms.
- Who are Damora Therapeutics's investors?
- Damora Therapeutics's investors include Access Biotechnology, Bay City Capital, EIR Ventures.
- How much funding has Damora Therapeutics raised?
- Damora Therapeutics has disclosed $428.3M raised across 3 rounds.
- Where is Damora Therapeutics headquartered?
- Damora Therapeutics is headquartered in Copenhagen, US.